La chaîne d'options affiche les données clés des options sur actions de Pharming à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Pharming..

Pharming (NASDAQ:PHAR) Stock, Chaîne d'Options

Pharming

Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming Group

PHARMARON BEIJING U/ADR by PHARMARON BEIJING CO LTD.

PHARNEXT by Pharnext

PHarol SGPS SA

PharmChem Inc

PHARMA FOODS INTL CO by Pharma Foods International Co., Ltd.

Pharma Foods International Co Ltd

Pharma Mar SA

PHARM-BIO SERV INC by Pharma-Bio Serv, Inc.

Pharma-Bio Serv Inc

PharmaCielo Ltd

PHARMACOM BIOVET INC by PharmaCom BioVet, Inc.

PharmaCom BioVet Inc

PharmaCyte Biotech Inc

PHARMAROTH LABS INC by PharmaRoth Labs, Inc.

PharmaRoth Labs Inc

PHARMATHER HLDGS LTD by PharmaTher Holdings Ltd.

PharmaTher Holdings Ltd

Pharmadrug Inc

Pharmagen Inc

PHARMAGREEN BIOTECH INC by Pharmagreen Biotech Inc.

Pharmagreen Biotech Inc

Pharmala Biotech Holdings Inc

PHARMALA BIOTECH HLDG INC by PharmAla Biotech Holdings Inc.

PHARMARON BEIJING CO LTD by PHARMARON BEIJING CO LTD.

Pharmaron Beijing Co Ltd

PHARMING GROUP NV ORD by Pharming Group NV

Pharnext SA

Pharos Energy PLC

Pharvaris NV

News

Press Releases

Pharming Group to participate in September investor conferences

General

Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)

Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation

Pharming Group to report third quarter 2024 financial results on October 24

Earnings

Pharming Group reports third quarter 2024 financial results and provides business update

Pharming Group to participate in November investor conference

Pharming announces positive topline data in pediatric clinical trial of leniolisib

Pharming announces public cash offer to the shareholders of Abliva AB

Management

Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer

Pharming Group to participate in February investor conference

PHAR

Absci

Abivax

AnaptysBio

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

Bicara Therapeutics

Candel Therapeutics

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Immatics

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharma

Kura Oncology

LENZ Therapeutics

MeiraGTx Hldgs

Opthea Limited - American Depositary Shares

Opthea

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Precigen

Relay Therapeutics

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Sana Biotechnology

Tectonic Therapeutic, Inc. - Common Stock

Comments

Pharming

Pharming (PHAR) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL